• Latest
  • Trending

Amarin versus generics: who will win? – Motley madman

22.11.2020
Buy downside with Apple, Microsoft and other tech stocks before they soar higher, analyst says – MarketWatch

Buy downside with Apple, Microsoft and other tech stocks before they soar higher, analyst says – MarketWatch

04.03.2021
The Biggest Moves in the Pre-Market: Okta, Marvell Technology, Vroom and more

The Biggest Moves in the Pre-Market: Okta, Marvell Technology, Vroom and more

04.03.2021
Carl Froch challenges Jake Paul and Logan Paul to call him after Floyd Mayweather and Conor McGregor videos: ‘I’ll smash them all to pieces’

Carl Froch challenges Jake Paul and Logan Paul to call him after Floyd Mayweather and Conor McGregor videos: ‘I’ll smash them all to pieces’

04.03.2021
Huawei partners with BUET to create the first ICT Academy – Prothom Alo français

Huawei partners with BUET to create the first ICT Academy – Prothom Alo français

04.03.2021
F1 drivers to use sparkling wine again during podium celebrations

F1 drivers to use sparkling wine again during podium celebrations

04.03.2021
Newcastle Bust Up: Matt Ritchie reportedly called boss Steve Bruce a ‘coward’ in furious training ground row ahead of critical relegation clash with West Brom

Newcastle players accused of ‘serving’ Steve Bruce after Matt Ritchie row as Simon Jordan calls ‘agenda’ against Magpies boss

04.03.2021
With 2021 NFL combine scrapped, former WR star Brandon Marshall has created his own event for draft contenders

With 2021 NFL combine scrapped, former WR star Brandon Marshall has created his own event for draft contenders

04.03.2021
Molly-Mae Hague Arch Backstage In New Glamor Photoshoot

Molly-Mae Hague Arch Backstage In New Glamor Photoshoot

04.03.2021
My nest is empty, but the stuff remains.  Why is decluttering so emotionally charged?

My nest is empty, but the stuff remains. Why is decluttering so emotionally charged?

04.03.2021
Britney Spears Net Worth Revealed – And She’s Insanely Low Compared To Her Pop Peers – Forbes

Britney Spears Net Worth Revealed – And She’s Insanely Low Compared To Her Pop Peers – Forbes

04.03.2021
‘Raya and the Last Dragon’ review: Deceive me once

‘Raya and the Last Dragon’ review: Deceive me once

04.03.2021
As Senate sends $ 1.9 trillion bill to Congress, Biden faces doubts whether it is still the right package – The Washington Post

As Senate sends $ 1.9 trillion bill to Congress, Biden faces doubts whether it is still the right package – The Washington Post

04.03.2021
Thursday, March 4, 2021
  • World
  • Economics
  • Sport
    • Basketball
    • Football
    • Nfl
    • Golf
    • F1
    • UFC
  • Technology
  • Culture
    • Arts
  • Media
    • Film
    • Celebs
    • TV
  • LifeStyle
    • Auto
  • Travel
OLTNEWS
  • World
  • Economics
  • Sport
    • Basketball
    • Football
    • Nfl
    • Golf
    • F1
    • UFC
  • Technology
  • Culture
    • Arts
  • Media
    • Film
    • Celebs
    • TV
  • LifeStyle
    • Auto
  • Travel
OLTNEWS
No Result
View All Result

Home » Economics » Amarin versus generics: who will win? – Motley madman

Amarin versus generics: who will win? – Motley madman

3 months ago
in Economics
0
0
SHARES
Share on WhatsappShare on Facebook

Related posts

The Biggest Moves in the Pre-Market: Okta, Marvell Technology, Vroom and more

The Biggest Moves in the Pre-Market: Okta, Marvell Technology, Vroom and more

04.03.2021
Global Upstream Oil and Gas Activities Market Report 2021 with Key Players – Saudi Aramco, Rosneft, Kuwait Petroleum Corporation, ADNOC, and Iraqi Ministry of Petroleum – GlobeNewswire

Global Upstream Oil and Gas Activities Market Report 2021 with Key Players – Saudi Aramco, Rosneft, Kuwait Petroleum Corporation, ADNOC, and Iraqi Ministry of Petroleum – GlobeNewswire

04.03.2021

My family’s wallets are filled with skyrocketing online retailers, skyrocketing software-as-a-service stocks, and vaccine biotech that has jumped 2,000%. This is my first year of writing for The Motley Fool, and at the same time the best year of my 20-year investment career. But I also had hiccups.

In an article, I advocated that investors buy shares of Cafe Luckin. The next day, the company said its income reports were fraudulent. But maybe my biggest failure was with Amarin (NASDAQ: AMRN). I have repeatedly suggested that investors might want to buy Irish biotech stocks because of the company’s incredible drug, Vascepa. In March, a Nevada trial judge struck down several patents for the drug. Amarin’s stock fell 70% overnight. Ouch.

Man with head on desk while stock market chart turns negative.

Image source: Getty Images.

I no longer bought shares of Amarin. For me, this market reaction was completely justified, given what happened in court. And yet, now that I’ve had time to think about it, I see a bullish case for Amarin (especially at these prices).

Amarin may lose patent fight against Vascepa and still win prescription war

Why did Wall Street hit Amarin? The stock market is very familiar with the “patent cliff” and how pharmaceutical stocks in particular can be killed when drugs are no longer patented. So, for example, when Pfizer lost patent protection for Lipitor, billions of dollars in revenue evaporated.

The stock market assumes a similar fate awaits Amarin. But it is a strange situation. Unlike Pfizer, Amarin has not had the opportunity to develop the market for its drug. The United States Food and Drug Administration (FDA) only recently authorized the company to expand its label. At the time, Amarin and many of his shareholders saw a huge blockbuster opportunity with Vascepa. But this market must be built. Doctors must be educated. Amarin is the entity that will pay for all of this. If this Irish biotech leaves the American market, no one will be in the hospitals to defend Vascepa.

The generic manufacturers involved in the trial, Dr Reddy’s laboratories (NYSE: RDY) and Hikma Pharmaceuticals (OTC: HKMP.Y), will educate physicians about the wonders of icosapent ethyl (the generic version of Vascepa)? No. Growing consumer demand is not what generic drug makers are doing.

Other than that, these companies are actually banned from trying to market their drugs as beneficial to heart health.

Compare FDA labels

In May, Hikma received FDA approval for its generic Vascepa. The company label for the drug states that “icosapent ethyl is indicated as an adjunct to a diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.”

It was more or less the original Vascepa label. This is not surprising, because the patents that have been invalidated relate to the sale of Vascepa to people with very high triglyceride levels. It’s a small market opportunity, which is why Amarin has spent many years – and a lot of money – paying for a clinical trial to prove Vascepa beneficial for heart health.

So, in order for a generic company like Hikma to make a lot of money with icosapent ethyl, the company would have to hope that doctors would prescribe Hikma’s drug off-label. Doctors can do this, of course, it’s not illegal. But why would a doctor prescribe an off-label generic when you have an inexpensive drug, Vascepa, approved by the FDA to improve heart health?

Here is the new Amarin label: “The US Food and Drug Administration [has] approved the use of Vascepa (icosapent ethyl) as an adjunct (secondary) treatment to reduce the risk of cardiovascular events in adults with high levels of triglycerides (a type of fat in the blood) by 150 milligrams per deciliter or more. ”

The Amarin label is much better than the Hikma label. Vascepa reduces the risk of cardiovascular events in a large class of people. The Hikma label reduces triglycerides in a small number of people.

Why should investors be bullish about Amarin?

It’s really bad news for Amarin (or any pharmaceutical company) when a drug isn’t approved by the FDA, either because it’s unsafe or because it doesn’t work. This is classic bad news for a pharmaceutical company. It can and will crash your stock.

The invalidation of several patents does not say anything about the effectiveness or the safety of a drug. This is bad news, but another kind of bad news.

Patents are important because they give you intellectual property rights, which means you can sue people and shut down all the other businesses that are trying to steal your income. The invalidation of some Amarin patents has opened the door to competition. But these generic companies are prohibited from marketing their drugs as improving heart health, while Amarin’s patents in this area are still strong.

This is not the only downside to generics. In a recent earnings call, Amarin CEO John Thero noted that while generic companies might have the ability to supply “to support tens of millions of dollars in revenue,” that amount didn’t represent ” that a small part “of what Vascepa – and Amarin – could possibly do.

Don’t forget Europe!

Of course, the big news for Amarin next year will be the approval of Vascepa in Europe. The company has already filed its MA application with the European Medicines Agency and the European Commission. If accepted, Amarin will be free to market Vascepa throughout Europe as reducing cardiovascular risk for appropriate patients.

There are over 80 million people in Europe with cardiovascular disease, so this opportunity is huge. And while the desirability of the U.S. market is much more obscure than it was, the claim that generics will capture most of that market seems questionable at best. Interested healthcare investors may find Amarin a worthwhile buy at these prices.



Share this:

  • Twitter
  • Facebook

Like this:

Like Loading...

Related

Previous Post

Man City to finish above Tottenham this season despite Jose Mourinho’s side’s brilliant start, says Tony Cascarino

Next Post

Survivor Series 2020: 5 WWE Superstars Who Desperately Need To Win PPV – Sportskeeda

Related Posts

The Biggest Moves in the Pre-Market: Okta, Marvell Technology, Vroom and more
Economics

The Biggest Moves in the Pre-Market: Okta, Marvell Technology, Vroom and more

04.03.2021
0

Take a look at some of the biggest players in the pre-market:Okta (OKTA) - Okta posted a 10.5% gain in...

Read more
Global Upstream Oil and Gas Activities Market Report 2021 with Key Players – Saudi Aramco, Rosneft, Kuwait Petroleum Corporation, ADNOC, and Iraqi Ministry of Petroleum – GlobeNewswire

Global Upstream Oil and Gas Activities Market Report 2021 with Key Players – Saudi Aramco, Rosneft, Kuwait Petroleum Corporation, ADNOC, and Iraqi Ministry of Petroleum – GlobeNewswire

04.03.2021
Stocks and Futures Fall as T-Bills Lose: Markets Pull Back

US futures fall as bond yields stabilize: markets collapse – Yahoo Finance

04.03.2021

US $ 1.1 billion player tries to break into European ETF market with climate focus – citywireselector.com

04.03.2021

Aon collaborates with Nayms on cryptocurrency launch – insurance business ASIA

04.03.2021

Reif Oil receives 2021 Renewable Fuels Marketing Award – KCRG

04.03.2021
Load More
Next Post
Survivor Series 2020: 5 WWE Superstars Who Desperately Need To Win PPV – Sportskeeda

Survivor Series 2020: 5 WWE Superstars Who Desperately Need To Win PPV - Sportskeeda

Recent Posts

  • Buy downside with Apple, Microsoft and other tech stocks before they soar higher, analyst says – MarketWatch
  • The Biggest Moves in the Pre-Market: Okta, Marvell Technology, Vroom and more
  • Carl Froch challenges Jake Paul and Logan Paul to call him after Floyd Mayweather and Conor McGregor videos: ‘I’ll smash them all to pieces’
  • Huawei partners with BUET to create the first ICT Academy – Prothom Alo français
  • F1 drivers to use sparkling wine again during podium celebrations

Archives

  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • EN

© 2020

No Result
View All Result
  • World
  • Economics
  • Sport
    • Basketball
    • Football
    • Nfl
    • Golf
    • F1
    • UFC
  • Technology
  • Culture
    • Arts
  • Media
    • Film
    • Celebs
    • TV
  • LifeStyle
    • Auto
  • Travel

© 2020

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.
%d bloggers like this: